SLS:NASDAQ, SELLAS Life Sciences Group, Inc.
Why SLS stock fell on November 5
SELLAS Life Sciences Group, Inc. fell 13.8%
on Thursday, November 5, 2026, on 10,739,000 shares.
Headlines around the move:
SLS stock overview
SELLAS Life Sciences Group, Inc. (SLS:NASDAQ) closed at $8.37 on November 10, 2026,
down 2.45% on the day.
The stock trades 47.3% below its 52-week high of $15.88
and 502.2% above its 52-week low of $1.39.
Over the past year, it gained 454.3%.
SELLAS Life Sciences Group, Inc. is part of the Health Care sector (Major Pharmaceuticals).
Key figures
- Price
- $8.37
- Day change
- -2.45%
- Volume
- 3,915,475
- Average volume
- 6,925,190
- Market cap
- 1B+
- 52-week range
- $1.39 – $15.88
- 50-day average
- $11.47
- 200-day average
- $8.70
Price action over the past year
In 252 trading sessions since November 10, 2025, SLS closed higher on 133 days (53%).
Its best day was May 13, 2026 (+25.10%) and its worst was January 6, 2026 (-18.00%).
The stock moved 10% or more in a single session 36 times.
It opened at least 5% above the previous day's high 7 times.
Recent signals
SLS news
-
Nov 10, 2026:
SLS Stock Rises Overnight: Retail Bets The Regal Wait Is Almost Over — Here's What Wall Street Expects From Earnings
-
Nov 10, 2026:
SLS Stock Rises Overnight: Retail Bets The Regal Wait Is Almost Over Heres What Wall Street Expects From Earnings
-
Nov 9, 2026:
Barclays, Deutsche Bank Reveal Stakes In Retail-Favorite Cancer Stocks SLS, IBRX And IOVA — Geode Adds More
-
Nov 9, 2026:
Barclays, Deutsche Bank Reveal Stakes In Retail-Favorite Cancer Stocks SLS, IBRX And IOVA Geode Adds More
-
Nov 6, 2026:
SELLAS Life Sciences Group (SLS) Stock Could Be Fully Priced On Phase 3 Analysis Trigger
-
Nov 5, 2026:
SLS Stock Rises Overnight Despite Citi's 64% Stake Cut — Retail Bulls Say SLS009 Alone Could Outvalue Sellas
-
Nov 5, 2026:
SLS Stock Rises Overnight Despite Citis 64% Stake Cut Retail Bulls Say SLS009 Alone Could Outvalue Sellas
-
Nov 4, 2026:
Sellas To Present SLS009 Data At American Society of Hematology – Initial Results Of Therapy In Newly Diagnosed AML Patients Expected In Q4
About SELLAS Life Sciences Group, Inc.
Galena Biopharma Inc is a biopharmaceutical company. It is focused on developing and commercializing targeted oncology therapeutics that addresses unmet medical needs.
Similar stocks
Find more stocks like SLS with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.